AngioDynamics Inc (ANGO) reported its fiscal Q2 2025 results with total revenue of $73 million, marking a 9.2% growth year-over-year, primarily driven by strong performance within its MedTech segment, which saw a 25% increase in revenue. Despite posting a net income loss of $10.7 million for the quarter, management has expressed optimism regarding the company’s trajectory towards profitability with positive adjusted EBITDA of $3.1 million and expectations of sustained profitability moving forward. Improved performance metrics reinforce the company’s strategic pivot towards high-growth MedTech markets, whereby adjusted EBITDA is projected to be positive for the full year, showcasing effective cost management and revenue growth strategies.